Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTK2 | Q05397 | 10/20 | 0.54 |
| ▸ | PTK2B | Q14289 | 6/20 | 0.54 |
| ▸ | IGF1R | P08069 | 4/20 | 0.42 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.42 |
| ▸ | KDR | P35968 | 2/20 | 0.42 |
| ▸ | JAK3 | P52333 | 1/20 | 0.42 |
| ▸ | EGFR | P00533 | 2/20 | 0.39 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.39 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.39 |
| ▸ | CDK1 | P06493 | 2/20 | 0.38 |
| ▸ | CDK2 | P24941 | 2/20 | 0.38 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.38 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.38 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.38 |
| ▸ | ITK | Q08881 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6211101 | 0.94 | PTK2 (0.50) | PTK2PTK2BIGF1RFGFR1KDR | |
| SCHEMBL6211840 | 0.88 | PTK2 (0.55) | PTK2PTK2BIGF1RFGFR1KDR | |
| SCHEMBL6212548 | 0.88 | PTK2 (0.50) | PTK2PTK2BIGF1RFGFR1KDR | |
| SCHEMBL6210196 | 0.85 | PTK2 (0.50) | PTK2PTK2BIGF1RFGFR1KDR | |
| SCHEMBL6212415 | 0.83 | PTK2 (0.59) | PTK2PTK2BIGF1RFGFR1KDR | |
| SCHEMBL6833054 | 0.82 | PTK2 (0.49) | PTK2PTK2BIGF1RFGFR1KDR | |
| SCHEMBL6212887 | 0.81 | PTK2 (0.55) | PTK2PTK2BIGF1RFGFR1KDR | |
| SCHEMBL6210330 | 0.81 | PTK2 (0.56) | PTK2PTK2BIGF1RFGFR1KDR | |
| SCHEMBL6216143 | 0.81 | PTK2 (0.75) | PTK2PTK2BIGF1RFGFR1KDR | |
| SCHEMBL6210610 | 0.78 | PTK2 (0.48) | PTK2PTK2BIGF1RFGFR1KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040220177-A1 | Compound for the treatment of abnormal cell growth | PFIZER INC | 2004-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040220177-A1 | Compound for the treatment of abnormal cell growth | CCNA1, CCNB1, CCNT1 | PTK2 3004/4885PTK2B 1941/4885IGF1R 93/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.